FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)

23

KENILWORTH, N.J.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank">$MRK</a> <a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank">#MRK</a>–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) as determined by an FDA-approved test, with disease progression after one or more pr http://www.businesswire.com/news/home/20190731005305/en/FDA-Approves-New-Monotherapy-Indication-Merck%E2%80%99s-KEYTRUDA%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J